{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:23:24Z","timestamp":1789809804690,"version":"4.0.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770209"],"award-info":[{"award-number":["81770209"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.gendis.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T12:48:49Z","timestamp":1656247729000},"page":"891-900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies"],"prefix":"10.1016","volume":"10","author":[{"given":"Tao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6572-1541","authenticated-orcid":false,"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0165-2478(00)00276-5","article-title":"Identification of human homologue of mouse IFN-gamma induced protein from human dendritic cells","volume":"74","author":"Li","year":"2000","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib2","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1038\/s41467-020-16983-2","article-title":"Crystal structures of SAMHD1 inhibitor complexes reveal the mechanism of water-mediated dNTP hydrolysis","volume":"11","author":"Morris","year":"2020","journal-title":"Nat Commun"},{"issue":"7377","key":"10.1016\/j.gendis.2022.06.001_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature10623","article-title":"HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase","volume":"480","author":"Goldstone","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib4","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1038\/s41467-021-24802-5","article-title":"SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in non-cycling cells","volume":"12","author":"Martinat","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.gendis.2022.06.001_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ng.373","article-title":"Mutations involved in Aicardi-Gouti\u00e8res syndrome implicate SAMHD1 as regulator of the innate immune response","volume":"41","author":"Rice","year":"2009","journal-title":"Nat Genet"},{"issue":"7353","key":"10.1016\/j.gendis.2022.06.001_bib6","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nature10117","article-title":"SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx","volume":"474","author":"Laguette","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.gendis.2022.06.001_bib7","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1128\/JVI.00155-14","article-title":"Identification of cellular proteins interacting with the retroviral restriction factor SAMHD1","volume":"88","author":"St Gelais","year":"2014","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.gendis.2022.06.001_bib8","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nm.4163","article-title":"SAMHD1-mediated HIV-1 restriction in cells does not involve ribonuclease activity","volume":"22","author":"Antonucci","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.gendis.2022.06.001_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.763151","article-title":"SAMHD1 mutations and expression in mantle cell lymphoma patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41408-017-0036-5","article-title":"SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia","volume":"8","author":"Johansson","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.gendis.2022.06.001_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/leu.2017.177","article-title":"Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups","volume":"32","author":"Burns","year":"2018","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.gendis.2022.06.001_bib12","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood-2015-05-647578","article-title":"Presence of multiple recurrent mutations confers poor trial outcome of relapsed\/refractory CLL","volume":"126","author":"Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib13","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ijc.33202","article-title":"The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: an analysis of the MCL Younger and Elderly trial","volume":"148","author":"Roider","year":"2021","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.gendis.2022.06.001_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.gendis.2022.06.001_bib15","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1158\/1078-0432.CCR-15-3103","article-title":"A quantitative analysis of subclonal and clonal gene mutations before and after therapy in chronic lymphocytic leukemia","volume":"22","author":"Amin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.gendis.2022.06.001_bib16","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1182\/blood-2012-05-433540","article-title":"Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns","volume":"120","author":"Schuh","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.gendis.2022.06.001_bib17","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1073\/pnas.1519128113","article-title":"Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance","volume":"113","author":"Rentoft","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.17352","article-title":"Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma","volume":"193","author":"Xagoraris","year":"2021","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/cancers14030641","article-title":"Modulation of DNA damage response by SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase (SAMHD1) determines prognosis and treatment efficacy in different solid tumor types","volume":"14","author":"Felip","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.gendis.2022.06.001_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat Med"},{"issue":"35","key":"10.1016\/j.gendis.2022.06.001_bib21","doi-asserted-by":"crossref","first-page":"14272","DOI":"10.1073\/pnas.1312033110","article-title":"The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells","volume":"110","author":"Franzolin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.gendis.2022.06.001_bib22","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1038\/ncomms3722","article-title":"Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase","volume":"4","author":"Zhu","year":"2013","journal-title":"Nat Commun"},{"issue":"49","key":"10.1016\/j.gendis.2022.06.001_bib23","doi-asserted-by":"crossref","first-page":"29428","DOI":"10.1074\/jbc.M115.663658","article-title":"Structural insights into the high-efficiency catalytic mechanism of the sterile \u03b1-motif\/histidine-aspartate domain-containing protein","volume":"290","author":"Li","year":"2015","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.gendis.2022.06.001_bib24","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nsmb.2692","article-title":"Mechanism of allosteric activation of SAMHD1 by dGTP","volume":"20","author":"Ji","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00428-021-03228-w","article-title":"Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma","volume":"480","author":"Merrien","year":"2022","journal-title":"Virchows Arch"},{"issue":"11","key":"10.1016\/j.gendis.2022.06.001_bib26","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.tim.2015.08.002","article-title":"SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction","volume":"23","author":"Ballana","year":"2015","journal-title":"Trends Microbiol"},{"issue":"9","key":"10.1016\/j.gendis.2022.06.001_bib27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/15384101.2018.1480216","article-title":"The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592","volume":"17","author":"Tramentozzi","year":"2018","journal-title":"Cell Cycle"},{"issue":"21","key":"10.1016\/j.gendis.2022.06.001_bib28","doi-asserted-by":"crossref","first-page":"13279","DOI":"10.1074\/jbc.M115.646588","article-title":"CyclinA2-cyclin-dependent kinase regulates SAMHD1 protein phosphohydrolase domain","volume":"290","author":"Yan","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2022.06.001_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.724870","article-title":"SAMHD1 phosphorylation at T592 regulates cellular localization and S-phase progression","volume":"8","author":"Batalis","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"8","key":"10.1016\/j.gendis.2022.06.001_bib30","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","article-title":"SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination","volume":"20","author":"Daddacha","year":"2017","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.gendis.2022.06.001_bib31","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/nar\/gkab051","article-title":"SAMHD1 restrains aberrant nucleotide insertions at repair junctions generated by DNA end joining","volume":"49","author":"Akimova","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"10.1016\/j.gendis.2022.06.001_bib32","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019102931","article-title":"SAMHD1-mediated dNTP degradation is required for efficient DNA repair during antibody class switch recombination","volume":"39","author":"Husain","year":"2020","journal-title":"EMBO J"},{"issue":"19","key":"10.1016\/j.gendis.2022.06.001_bib33","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1073\/pnas.1719771115","article-title":"SAMHD1 enhances immunoglobulin hypermutation by promoting transversion mutation","volume":"115","author":"Thientosapol","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.gendis.2022.06.001_bib34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ncb3586","article-title":"Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence","volume":"19","author":"Gl\u00fcck","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"7703","key":"10.1016\/j.gendis.2022.06.001_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41586-018-0050-1","article-title":"SAMHD1 acts at stalled replication forks to prevent interferon induction","volume":"557","author":"Coquel","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gendis.2022.06.001_bib36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.gendis.2022.06.001_bib37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.celrep.2019.06.027","article-title":"SAMHD1 modulates early steps during human cytomegalovirus infection by limiting NF-\u03baB activation","volume":"28","author":"Kim","year":"2019","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib38","doi-asserted-by":"crossref","first-page":"e01970","DOI":"10.1128\/JVI.01970-20","article-title":"TRAF6 and TAK1 contribute to SAMHD1-mediated negative regulation of NF-\u03baB signaling","volume":"95","author":"Espada","year":"2021","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.gendis.2022.06.001_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tig.2021.10.002","article-title":"Classical and noncanonical functions of miRNAs in cancers","volume":"38","author":"Dragomir","year":"2022","journal-title":"Trends Genet"},{"key":"10.1016\/j.gendis.2022.06.001_bib40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12974-015-0285-9","article-title":"Sterile alpha motif and histidine\/aspartic acid domain-containing protein 1 (SAMHD1)-facilitated HIV restriction in astrocytes is regulated by miRNA-181a","volume":"12","author":"Pilakka-Kanthikeel","year":"2015","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.gendis.2022.06.001_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2016.11.010","article-title":"MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from S\u00e8zary syndrome patients","volume":"52","author":"Kohnken","year":"2017","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbrc.2014.08.151","article-title":"MicroRNA-181 expression regulates specific post-transcriptional level of SAMHD1 expression in vitro","volume":"452","author":"Jin","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1074\/jbc.M116.752584","article-title":"Interferons induce expression of SAMHD1 in monocytes through down-regulation of miR-181a and miR-30a","volume":"292","author":"Riess","year":"2017","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.gendis.2022.06.001_bib44","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.celrep.2013.03.017","article-title":"Phosphorylation of SAMHD1 by cyclin A2\/CDK1 regulates its restriction activity toward HIV-1","volume":"3","author":"Cribier","year":"2013","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib45","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-018-04671-1","article-title":"Dephosphorylation of the HIV-1 restriction factor SAMHD1 is mediated by PP2A-B55\u03b1 holoenzymes during mitotic exit","volume":"9","author":"Schott","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.gendis.2022.06.001_bib46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.tcb.2021.01.010","article-title":"New insights into CDK regulators: novel opportunities for cancer therapy","volume":"31","author":"Bury","year":"2021","journal-title":"Trends Cell Biol"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188716","article-title":"Cyclin-dependent kinases in DNA damage response","volume":"1877","author":"Kciuk","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib48","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1038\/s41467-021-27124-8","article-title":"The NUCKS1-SKP2-p21\/p27 axis controls S phase entry","volume":"12","author":"Hume","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.gendis.2022.06.001_bib49","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1016\/j.celrep.2020.03.008","article-title":"TLR4-mediated pathway triggers interferon-independent G0 arrest and antiviral SAMHD1 activity in macrophages","volume":"30","author":"Mlcochova","year":"2020","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.gendis.2022.06.001_bib50","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.celrep.2018.06.090","article-title":"Functionality of redox-active cysteines is required for restriction of retroviral replication by SAMHD1","volume":"24","author":"Wang","year":"2018","journal-title":"Cell Rep"},{"issue":"16","key":"10.1016\/j.gendis.2022.06.001_bib51","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1089\/ars.2016.6888","article-title":"The SAMHD1 dNTP triphosphohydrolase is controlled by a redox switch","volume":"27","author":"Mauney","year":"2017","journal-title":"Antioxidants Redox Signal"},{"issue":"4","key":"10.1016\/j.gendis.2022.06.001_bib52","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1152\/physrev.00025.2019","article-title":"SUMO: from bench to bedside","volume":"100","author":"Chang","year":"2020","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13578-021-00636-y","article-title":"PIAS1 potentiates the anti-EBV activity of SAMHD1 through SUMOylation","volume":"11","author":"Saiada","year":"2021","journal-title":"Cell Biosci"},{"issue":"2","key":"10.1016\/j.gendis.2022.06.001_bib54","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7150\/thno.50230","article-title":"Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation","volume":"11","author":"Hu","year":"2021","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.gendis.2022.06.001_bib55","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2013-04-490847","article-title":"SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage","volume":"123","author":"Clifford","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41467-021-21023-8","article-title":"Nucleic acid binding by SAMHD1 contributes to the antiretroviral activity and is enhanced by the GpsN modification","volume":"12","author":"Yu","year":"2021","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.gendis.2022.06.001_bib57","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1021\/acs.chemrev.6b00209","article-title":"Metabolism, biochemical actions, and chemical synthesis of anticancer nucleosides, nucleotides, and base analogs","volume":"116","author":"Shelton","year":"2016","journal-title":"Chem Rev"},{"issue":"43","key":"10.1016\/j.gendis.2022.06.001_bib58","doi-asserted-by":"crossref","first-page":"E10022","DOI":"10.1073\/pnas.1805593115","article-title":"The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1","volume":"115","author":"Knecht","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.gendis.2022.06.001_bib59","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/15384101.2017.1314407","article-title":"SAMHD1 protects cancer cells from various nucleoside-based antimetabolites","volume":"16","author":"Herold","year":"2017","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s13046-021-02093-4","article-title":"Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells","volume":"40","author":"Rothenburger","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.gendis.2022.06.001_bib61","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-018-0134-z","article-title":"Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens","volume":"8","author":"Rassidakis","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib62","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910419","article-title":"Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy","volume":"12","author":"Rudd","year":"2020","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib63","doi-asserted-by":"crossref","first-page":"50","DOI":"10.15252\/embj.201796880","article-title":"DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages","volume":"37","author":"Mlcochova","year":"2018","journal-title":"EMBO J"},{"issue":"6","key":"10.1016\/j.gendis.2022.06.001_bib64","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2021013998","article-title":"Limited-stage diffuse large B-cell lymphoma","volume":"139","author":"Hawkes","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.gendis.2022.06.001_bib65","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1182\/blood.2019004044","article-title":"How I treat nodular lymphocyte-predominant Hodgkin lymphoma","volume":"136","author":"Eichenauer","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.gendis.2022.06.001_bib66","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood-2017-12-791418","article-title":"Advances in the treatment of extranodal NK\/T-cell lymphoma, nasal type","volume":"131","author":"Yamaguchi","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.gendis.2022.06.001_bib67","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.gendis.2022.06.001_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104266","article-title":"Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors","volume":"104","author":"Jaswal","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.gendis.2022.06.001_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102361","article-title":"Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers","volume":"105","author":"Wong","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.gendis.2022.06.001_bib70","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/biomedicines9050480","article-title":"Recent advances in improved anticancer efficacies of camptothecin nano-formulations: a systematic review","volume":"9","author":"Ghanbari-Movahed","year":"2021","journal-title":"Biomedicines"},{"issue":"24","key":"10.1016\/j.gendis.2022.06.001_bib71","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1158\/1078-0432.CCR-21-2139","article-title":"Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions","volume":"27","author":"Zavras","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gendis.2022.06.001_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100805","article-title":"Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"\u0160imoni\u010dov\u00e1","year":"2022","journal-title":"Drug Resist Updates"},{"issue":"21","key":"10.1016\/j.gendis.2022.06.001_bib73","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib74","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2 \u00d7 2, phase II trial","volume":"38","author":"L\u00fcbbert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.gendis.2022.06.001_bib75","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.20.02619","article-title":"Phase III, randomized, placebo-controlled trial of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes","volume":"39","author":"Garcia-Manero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2022.06.001_bib76","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib77","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-019-11413-4","article-title":"Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML","volume":"10","author":"Oellerich","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.gendis.2022.06.001_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications - cause and consequence of genome function","author":"Mill\u00e1n-Zambrano","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"7","key":"10.1016\/j.gendis.2022.06.001_bib79","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202152774","article-title":"Histone acylations and chromatin dynamics: concepts, challenges, and links to metabolism","volume":"22","author":"Nitsch","year":"2021","journal-title":"EMBO Rep"},{"issue":"9","key":"10.1016\/j.gendis.2022.06.001_bib80","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.gendis.2022.06.001_bib81","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib82","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.gendis.2022.06.001_bib83","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib84","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","article-title":"Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study","volume":"22","author":"Laubach","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2022.06.001_bib85","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2022.06.001_bib86","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s12272-015-0571-1","article-title":"Histone deacetylase inhibitors in hematological malignancies and solid tumors","volume":"38","author":"Chun","year":"2015","journal-title":"Arch Pharm Res (Seoul)"},{"issue":"5","key":"10.1016\/j.gendis.2022.06.001_bib87","doi-asserted-by":"crossref","first-page":"604","DOI":"10.15252\/embj.201696025","article-title":"A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages","volume":"36","author":"Mlcochova","year":"2017","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.gendis.2022.06.001_bib88","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/pharmaceutics13122201","article-title":"The TKI era in chronic leukemias","volume":"13","author":"De Novellis","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.gendis.2022.06.001_bib89","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1172\/JCI68951","article-title":"PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells","volume":"123","author":"Neviani","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gendis.2022.06.001_bib90","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcp.2016.02.002","article-title":"Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells","volume":"106","author":"Bermejo","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib91","doi-asserted-by":"crossref","first-page":"e00819","DOI":"10.1128\/mBio.00819-18","article-title":"SAMHD1 phosphorylation coordinates the anti-HIV-1 response by diverse interferons and tyrosine kinase inhibition","volume":"9","author":"Szaniawski","year":"2018","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.gendis.2022.06.001_bib92","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7482","key":"10.1016\/j.gendis.2022.06.001_bib93","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature12815","article-title":"Structural basis of lentiviral subversion of a cellular protein degradation pathway","volume":"505","author":"Schwefel","year":"2014","journal-title":"Nature"},{"issue":"7353","key":"10.1016\/j.gendis.2022.06.001_bib94","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nature10195","article-title":"Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein","volume":"474","author":"Hrecka","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gendis.2022.06.001_bib95","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.4265","article-title":"Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies","volume":"23","author":"Herold","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.gendis.2022.06.001_bib96","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers12030713","article-title":"Pharmacological modulation of SAMHD1 activity by CDK4\/6 inhibitors improves anticancer therapy","volume":"12","author":"Castellv\u00ed","year":"2020","journal-title":"Cancers"},{"issue":"47","key":"10.1016\/j.gendis.2022.06.001_bib97","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1021\/acs.biochem.8b01038","article-title":"Identification of inhibitors of the dNTP triphosphohydrolase SAMHD1 using a novel and direct high-throughput assay","volume":"57","author":"Mauney","year":"2018","journal-title":"Biochemistry"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222001751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304222001751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:34:43Z","timestamp":1762450483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304222001751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2352304222001751"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2022.06.001","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting SAMHD1: To overcome multiple anti-cancer drugs resistance in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}